{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:53:23Z","timestamp":1788314003455,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004322","name":"Agilent Technologies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.clml.2018.12.013","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T12:06:04Z","timestamp":1546430764000},"page":"275-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Phase 2 Study of Daratumumab in Relapsed\/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Wakamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaibao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Schecter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.12.013_bib1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1586\/14737140.2015.1023712","article-title":"New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy","volume":"15","author":"Chihara","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2018.12.013_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CMAR.S34273","article-title":"Treatment challenges in the management of relapsed or refractory non-Hodgkin\u2019s lymphoma\u2014novel and emerging therapies","volume":"5","author":"Chao","year":"2013","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clml.2018.12.013_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clml.2018.12.013_bib4","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2018.12.013_bib5","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in\u00a0vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79","volume":"124","author":"Lammerts van Bueren","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.013_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.clml.2018.12.013_bib7","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2018.12.013_bib8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2018.12.013_bib9","first-page":"138","article-title":"Daratumumab treatment in combination with chop or R-CHOP results in the inhibition or regression of tumors in preclinical models of non-Hodgkins lymphoma","volume":"99","author":"Doshi","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.12.013_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hon.2437_29","article-title":"Antitumoral activity of Daratumumab, a novel human CD38 monoclonal antibody, in B-cell non-Hodgkin lymphoma in\u00a0vitro and in\u00a0vivo models","volume":"35","author":"Matas-C\u00e9spedes","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.12.013_bib11","series-title":"Development of a clinical trial immunohistochemistry (IHC) assay using a novel antibody to CD38","author":"Wakamiya","year":"2017"},{"key":"10.1016\/j.clml.2018.12.013_bib12","series-title":"Darzalex\u00ae (Daratumumab) Injection, for Intravenous Use [Package Insert]","year":"2018"},{"key":"10.1016\/j.clml.2018.12.013_bib13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.013_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","article-title":"Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review","volume":"14","author":"Camicia","year":"2015","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clml.2018.12.013_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.013_bib17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ajh.24094","article-title":"Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management","volume":"90","author":"Vose","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.12.013_bib18","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international Scholar-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.013_bib19","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","article-title":"FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma","volume":"21","author":"Miller","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.12.013_bib20","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s40265-017-0838-6","article-title":"Copanlisib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.clml.2018.12.013_bib21","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1200\/JCO.2017.35.15_suppl.7535","article-title":"Copanlisib in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.013_bib22","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-14-0010","article-title":"Ibrutinib for the treatment of mantle cell lymphoma","volume":"20","author":"Herrera","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.12.013_bib23","series-title":"Imbruvica\u00ae (Ibrutinib) [Package Insert]","year":"2018"},{"key":"10.1016\/j.clml.2018.12.013_bib24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.12.013_bib25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.12.013_bib26","series-title":"Calquence\u00ae (Acalabrutinib) [Package Insert]","year":"2017"},{"key":"10.1016\/j.clml.2018.12.013_bib27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.12.013_bib28","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.013_bib29","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","article-title":"Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment","volume":"56","author":"Clemens","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clml.2018.12.013_bib30","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.12.013_bib31","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.12.013_bib32","doi-asserted-by":"crossref","first-page":"e1217374","DOI":"10.1080\/2162402X.2016.1217374","article-title":"Immunotherapies targeting CD38 in multiple myeloma","volume":"5","author":"Atanackovic","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clml.2018.12.013_bib33","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.12.013_bib34","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.12.013_bib35","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.12.013_bib36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2017-09-807610","article-title":"CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.013_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.013_bib38","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and\u00a0dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of Pollux","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.12.013_bib39","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of Castor","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.12.013_bib40","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJMc1605684","article-title":"Targeting CD38 in refractory extranodal natural killer cell\u2013T-cell lymphoma","volume":"375","author":"Hari","year":"2016","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018312849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018312849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:02Z","timestamp":1761870722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018312849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S2152265018312849"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.12.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Study of Daratumumab in Relapsed\/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}